Amy E Levenson1, Amy S Shah2, Philip R Khoury3, Thomas R Kimball3, Elaine M Urbina3, Sarah D de Ferranti4, David M Maahs5, Lawrence M Dolan2, R Paul Wadwa5, Sudha B Biddinger1. 1. Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Division of Endocrinology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio. 3. Division of Cardiology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio. 4. Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, Colorado.
Abstract
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein cholesterol and cardiovascular disease risk, and is an emerging therapeutic target. OBJECTIVE: We compared serum PCSK9 levels in young adults, with and without type 2 diabetes. SUBJECTS AND METHODS: Cross-sectional analysis was conducted in a cohort, aged 15 to 26 years, in Cincinnati, OH, from 2005 to 2010. Serum PCSK9 levels were measured in 94 youth with type 2 diabetes, 93 obese control subjects, and 99 lean control subjects. Correlative analyses were conducted to determine significant covariates of PCSK9 by group and sex, and multivariate linear regression models were used to study the independent determinants of PCSK9. RESULTS: In females, PCSK9 levels were significantly increased in the obese and type 2 diabetes subjects relative to the lean controls (P < .01). Moreover, PCSK9 was positively correlated with multiple metabolic parameters in females: body mass index, systolic blood pressure, fasting glucose, fasting insulin, and C-reactive protein levels (P ≤ .02). In males, PCSK9 levels were decreased overall compared with females (P = .03), and did not differ between the lean, obese, or type 2 diabetes groups. CONCLUSIONS: Obesity and type 2 diabetes were associated with significantly higher levels of PCSK9 in young women, but not in young men. These data suggest that sex could modify the effects of obesity and diabetes on PCSK9 in young adults.
BACKGROUND:Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein cholesterol and cardiovascular disease risk, and is an emerging therapeutic target. OBJECTIVE: We compared serum PCSK9 levels in young adults, with and without type 2 diabetes. SUBJECTS AND METHODS: Cross-sectional analysis was conducted in a cohort, aged 15 to 26 years, in Cincinnati, OH, from 2005 to 2010. Serum PCSK9 levels were measured in 94 youth with type 2 diabetes, 93 obese control subjects, and 99 lean control subjects. Correlative analyses were conducted to determine significant covariates of PCSK9 by group and sex, and multivariate linear regression models were used to study the independent determinants of PCSK9. RESULTS: In females, PCSK9 levels were significantly increased in the obese and type 2 diabetes subjects relative to the lean controls (P < .01). Moreover, PCSK9 was positively correlated with multiple metabolic parameters in females: body mass index, systolic blood pressure, fasting glucose, fasting insulin, and C-reactive protein levels (P ≤ .02). In males, PCSK9 levels were decreased overall compared with females (P = .03), and did not differ between the lean, obese, or type 2 diabetes groups. CONCLUSIONS:Obesity and type 2 diabetes were associated with significantly higher levels of PCSK9 in young women, but not in young men. These data suggest that sex could modify the effects of obesity and diabetes on PCSK9 in young adults.
Authors: M C G J Brouwers; J S Troutt; M M J van Greevenbroek; I Ferreira; E J Feskens; C J H van der Kallen; N C Schaper; C G Schalkwijk; R J Konrad; C D A Stehouwer Journal: Atherosclerosis Date: 2011-03-25 Impact factor: 5.162
Authors: Bruno Vergès; Laurence Duvillard; Marie Claude Brindisi; Emmanuel Gautier; Michel Krempf; Philippe Costet; Bertrand Cariou Journal: Atherosclerosis Date: 2011-07-26 Impact factor: 5.162
Authors: Ji Miao; Praveen V Manthena; Mary E Haas; Alisha V Ling; Dong-Ju Shin; Mark J Graham; Rosanne M Crooke; Jingwen Liu; Sudha B Biddinger Journal: Arterioscler Thromb Vasc Biol Date: 2015-05-28 Impact factor: 8.311
Authors: Laura N McEwen; Andrew J Karter; Beth E Waitzfelder; Jesse C Crosson; David G Marrero; Carol M Mangione; William H Herman Journal: Diabetes Care Date: 2012-03-19 Impact factor: 19.112
Authors: Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Kathryn A Williams; R Paul Wadwa; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; Amy S Shah; Clary B Clish; Sudha B Biddinger Journal: Pediatr Diabetes Date: 2020-09-15 Impact factor: 4.866
Authors: Amy E Levenson; R Paul Wadwa; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; Franziska K Bishop; David M Maahs; Lawrence M Dolan; Sudha B Biddinger Journal: Diabetes Care Date: 2017-06-06 Impact factor: 19.112